Medibio : Investor Presentation December 2021

nal use only

INVESTOR DECK

ASX: MEB

OTCPINK: MDBIF

DECEMBER 2021

FORWARD LOOKING STATEMENTS

F O R W A R D L O O K I N G	The purpose of the presentation is to provide an update
S T A T E M E N T S	of
the business of Medibio Limited (ASX:MEB) (OTCPINK:
	MDBIF). These slides have been prepared as a
	presentation aid only and the information they contain
	may require further explanation and/or clarification.
Accordingly, these slides and the information they contain should be read in	uncertainties and other factors, many of which are outside Medibio Limited's control.
c njunction with past and future announcements made by Medibio Limited and should	Important factors that could cause actual results to differ materially from assumptions
n t be relied upon as an independent source of information. Please contact Medibio
or expectations expressed or implied in this presentation include known and unknown
only
Limited and/or refer to the Company's website for further information. The views	risks.
expressed in this presentation contain information derived from publicly available
use
sources that have not been independently verified.	Because actual results could differ materially to assumptions made and Medibio
None of Medibio Limited, or any of its affiliates or associated companies(or any of their	Limited's current intentions, plans, expectations and beliefs about the future, you are
officers, employees, contractors or agents (the Relevant Persons)) makes any	urged to view all forward looking statements contained in this presentation with
representation or warranty as to the accuracy, completeness or reliability of the	caution. Except as required by applicable law or the ASX listing rules, the Relevant
information, or the likelihood of fulfilment of any forward looking statement or any
Persons disclaim any obligation or undertaking to publicly update any statements in this
o tcomes expressed or implied in any forward looking statements.
presentation, whether as a result of new information or future events.
Any forward looking statements in this presentation have been prepared on the basis	This presentation should not be relied on as a
of a number of assumptions which may prove incorrect and the current intentions,	recommendation or forecast by Medibio Limited. Nothing in
p ans, expectations and beliefs about future events are subject to risks,
nal	this presentation constitutes investment advice or should be
	construed as either an offer to sell or a solicitation of an offer
© 2021 Medibio Limited	to buy or sell shares in any jurisdiction.

only	Looking at Mental Health Objectively
use	A mental health technology company pioneering the use of Artificial Intelligence, deep learning
algorithms and neural network methodology to identify biological markers and patterns to aid
	in early detection and screening of mental health conditions.
nal

© 2021 Medibio Limited

CHANGING SUBJECTIVITY TO OBJECTIVITY

onlyuseIdentification of biomarkers and patterns based on the patient's own biological data to objectively aid in the

early detection and screening of mental health

conditions

nal© 2021 Medibio Limited

THE PROBLEM

Current diagnostic tests rely on clinical

interviews with subjective

interpretation

OUR SOLUTION

diagnosis of depression and other mental health disorders

nal© 2021 Medibio Limited

Targeting a Large Market

The potential to be the world's first objective diagnostic aid of a largely intangible health epidemic: depression

Innovative Technology

onlyuse Depression is estimated to cost US economy Medibio is a DigitalUS$210Mentalbillion a year with the cost in Australia Health pioneerestimatedwho has at $12.6 billion annually developed the first objective

testing system for the

Medibio's LUCA and ilumen gaining market traction: early revenue.

WHY INVEST IN MEDIBIO?

Early Revenue Potential

Superior Value Proposition

Objective, data-driven biological markers and patterns identified during sleep period rather than subjective assessment.

Regulatory Program

Validation trial underway for FDA De Novo Application

Patent Protected Technology

Method and System for Monitoring Stress Conditions Using Overnight Heart Rate

Method and System for Assessing Mental Health State Using Overnight Heart Rate